0000000000236467

AUTHOR

José Ernesto Moro-rodríguez

showing 2 related works from this author

Expression of clec9a in the oral cancer microenvironment. A preliminary immunohistochemical pilot study

2021

Background The search for treatments to improve cancer survival has led to the emergence of immunotherapy and the study of the tumour microenvironment existing in neoplasms. This preliminary study aims to understand the clinical and pathological relationship of clec9a expression in oral cancer and to explore survival models for future studies. Material and methods: Immunohistochemical study that included 26 patients with a diagnosis of oral squamous cell carcinoma (OSCC) in mobile tongue and floor of the mouth. Clinical and histopathological variables were recorded, and the biomarkers clec9a for dendritic cells and CD8 and CD4 for lymphocytes were used. Results Clec9a was expressed in 58% o…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPilot ProjectsInternal medicineOral Cancer and Potentially malignant disordersmedicineCarcinomaTumor MicroenvironmentHumansLectins C-TypepainGeneral DentistryPathologicalSurvival analysisUNESCO:CIENCIAS MÉDICASMouth neoplasmTumor microenvironmentbusiness.industryResearchquestionnaireCancerpsychometric validationImmunotherapymedicine.diseasePrognosisstomatognathic diseasesOtorhinolaryngologydisabilityHead and Neck NeoplasmsReceptors MitogenCarcinoma Squamous CellImmunohistochemistrySurgeryMouth Neoplasmshead and neck cancerbusiness
researchProduct

Oral mucositis. Is it present in the immunotherapy of the immune checkpoint pd1/pd-l1 against oral cancer? A systematic review

2020

Background Oral mucositis (OM) is a painful lesion that takes place in the mucosa of the oral cavity, usually its etiology is associated with drug therapies in cancer patients. It is presented as well-defined ulcers whose painful symptomatology sometimes implies the suspension of oncological treatment or parenteral feeding, being therefore an important adverse effect, marking the evolution of these types of therapies against cancer. The present work aim is to know the prevalence of oral mucositis in oral cancer immunotherapy compared to its prevalence in standard therapy. Material and Methods A protocol was developed for a systematic review following PRISMA® guidelines and a focused questio…

Oncologymedicine.medical_specialtymedicine.medical_treatmentReviewPembrolizumabB7-H1 Antigenperiapical lesionInternal medicinedifferential diagnosisMucositisHumansMedicineAdverse effectGeneral DentistryUNESCO:CIENCIAS MÉDICASStomatitisOral Medicine and PathologyCetuximabbusiness.industryCancerImmunotherapymedicine.diseasepulp necrosisClinical trialNivolumabOtorhinolaryngologynonendodonticMouth NeoplasmsSurgeryImmunotherapyNivolumabbusinessmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct